tiprankstipranks
Bioethics (BOTH)
OTHER OTC:BOTH
US Market
Holding BOTH?
Track your performance easily

Bioethics (BOTH) Income Statement

11 Followers

Bioethics Income Statement

Last quarter (Q ), Bioethics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Bioethics's net income was $73.91K. See Bioethics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ -47.30K$ -47.30K$ -59.37K$ -75.14K$ -70.03K$ -53.98K
Operating Income
$ 47.30K$ 47.30K$ -59.37K$ -75.14K$ -70.03K$ -53.98K
Net Non Operating Interest Income Expense
$ -45.90K$ -45.90K$ -47.82K$ -44.05K$ -31.88K$ -19.56K
Other Income Expense
---$ -6.20K$ -4.00K$ 73.54K
Pretax Income
$ -93.20K$ -93.20K$ -107.18K$ -119.19K$ -101.92K$ -73.54K
Tax Provision
-----$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 1.40K$ 1.40K$ -107.18K$ -119.19K$ -101.92K$ -73.54K
Basic EPS
$ -0.08$ -0.08$ -0.09$ -1.00$ -0.90-
Diluted EPS
--$ -0.09$ -1.00$ -0.90$ 0.00
Basic Average Shares
$ 3.41M$ 1.14M$ 1.14M$ 113.52K$ 113.52K$ 3.06M
Diluted Average Shares
$ 1.15M---$ 113.52K$ 0.00
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ -47.30K$ -47.30K$ -59.37K$ -75.14K$ -70.03K$ -53.98K
Net Income From Continuing And Discontinued Operation
$ 1.40K$ 1.40K$ -107.18K$ -119.19K$ -101.92K$ -73.54K
Normalized Income
------
Interest Expense
------
EBIT
$ -47.30K$ -47.30K$ -59.37K$ -75.14K$ -70.03K$ -53.98K
EBITDA
$ -47.30K$ -47.30K$ -56.42K$ -67.66K$ -69.46K$ -53.70K
Currency in USD

Bioethics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis